Key Takeaways:
- ReShape Lifesciences partners with Motion Informatics to distribute neuromuscular rehab devices in the U.S.
- The exclusive agreement aims to enhance neurorehabilitation for post-stroke or surgery patients.
- Reshape Lifesciences Inc (RSLS, Financial) shows a potential upside of 192.23% based on analyst price targets.
ReShape Lifesciences (RSLS) has strategically partnered with Motion Informatics for exclusive U.S. distribution of state-of-the-art neuromuscular rehabilitation devices. Among these is the FDA-cleared Stimel-03, designed to revolutionize neurorehabilitation for patients recovering from strokes or surgeries. This collaboration is a significant step towards providing advanced rehabilitation solutions that cater to growing patient needs.
Wall Street Analysts' Forecasts
Current analysis from Wall Street provides a compelling outlook for Reshape Lifesciences Inc (RSLS). With input from one analyst, the average one-year price target stands at $1.00, maintaining a consistent high and low estimate of $1.00. This suggests an impressive potential upside of 192.23% from the current market price of $0.34. For those interested in a more detailed breakdown of these estimates, further information is available on the Reshape Lifesciences Inc (RSLS, Financial) Forecast page.
In terms of brokerage recommendations, Reshape Lifesciences Inc's average rating reflects a "Hold" position, with an assessment score of 3.0 from the sole participating brokerage firm. This rating falls in the middle of the scale, which ranges from 1 (Strong Buy) to 5 (Sell), signaling a neutral stance on the stock's immediate future performance.
